



PATENT

Case Docket No. ELITRA.001A

Date: April 9, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Zyskind, et al.

Appl. No. : 09/492,709

Filed : January 27, 2000

For : GENES IDENTIFIED AS  
REQUIRED FOR  
PROLIFERATION IN  
ESCHERICHIA COLI

Examiner : A. Marschel

Group Art Unit : 1631

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with the  
) United States Postal Service as first class mail in  
) an envelope addressed to: United States Patent  
) and Trademark Office, P.O. Box 2327,  
) Arlington, VA 22202, on

April 9, 2003

(Date)

*Daniel Hart*

Daniel Hart, Reg. No. 40,637

TRANSMITTAL LETTER

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with three (3) references.
- (X) A check is enclosed in the amount of \$180 to cover the fees set forth in 37 C.F.R. §1.17(p).
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

*Daniel Hart*

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 20,995

(619) 235-8550

RECEIVED

APR 16 2003

TECH CENTER 1600/2900

ELITRA.001A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zyskind, et al. ) Group Art Unit 1631  
App. No. : 09/492,709 )  
Filed : January 27, 2000 )  
For : GENES IDENTIFIED AS REQUIRED )  
FOR PROLIFERATION IN )  
ESCHERICHIA COLI )  
Examiner : A. Marschel )

RECEIVED  
APR 16 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing three (3) references that are also enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

04/15/2003 HGUTEMA1 00000037 09492709

01 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 9, 2003

By: Daniel Hart

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 20,995

(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ELITRA.001AAPPLICATION NO.  
09/492,709SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Zyskind, et al.FILING DATE  
January 27, 2000GROUP  
1631

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

RECEIVED  
APR 16 2003  
TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bennett, F. C. 1998. Antisense oligonucleotides: Is the glass half full or half empty? <i>Biochemical Pharmacology</i> , 55:9-19.
	2	Crooke, S. T. 1998. An overview of progress in antisense therapeutics. <i>Antisense &amp; Nucleic Acid Drug Development</i> , 8:115-122.
	3	Gura, T. 1995. Antisense has growing pains. <i>Science</i> , 270:575-577.

S:\DOCS\DOH\DOH-7374.DOC:dmb  
032503

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.